Oramed Pharma (ORMP) Issues Letter to Shareholders

Go back to Oramed Pharma (ORMP) Issues Letter to Shareholders

Oramed Letter to Shareholders

February 20, 2024 8:30 AM EST

Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTITScilex Senior Secured NotePeriTech Asset Purchase & Strategic Out-licensing 

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals... More